AUTHORS
Yuan Yao, MD, MS, Sara J Achenbach2, Grant D. Shanafelt3, Paul J. Hampel, MD4, Lindsey Elizabeth Roeker, MD5, Yucai Wang, MD, PhD6, Aaron Norman7, Kari G Rabe, MS8, Janet E Olson, PhD9, Rosalie Griffin, PhD10, Bryan Vallejo11, George A Cholack, MD, MSc12, Stacey J. Lehman13, Timothy Call, MD14, James R. Cerhan, MD, PhD15, Celine Vachon, PhD16, Neil E Kay, M.D.17, Esteban Braggio, PhD18, Curtis A. Hanson, MD19, Nicholas J Boddicker, PhD20, Konstantinos Leventakos21, Sameer A. Parikh, MBBS22, Susan L. Slager, PhD23
AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 University of Nevada, Reno, Nevada, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Phoenix, Arizona, United States
19 Mayo Clinic, Rochester, Minnesota, United States
20 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
21 Mayo Clinic, Rochester, Minnesota, United States
22 Mayo Clinic, Rochester, Minnesota, United States
23 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Background: Monoclonal B-cell lymphocytosis (MBL) is a common premalignant condition characterized by the presence of a clonal B-cell population in peripheral blood. MBL is classified into two immunophenotypes: chronic lymphocytic leukemia (CLL)-type MBL and non-CLL type MBL. CLL-type MBL, the most common subtype and established precursor to CLL, can be further classified into high-count MBL (HC-MBL; <5% cases) and low-count MBL (LC-MBL; >95% cases). Although few individuals with LC-MBL progress to CLL, the condition may be associated with risk of other clinical sequelae. Prior studies have consistently reported an increased risk of lung cancer among individuals with CLL, with standardized incidence ratios ranging from 1.4 to 2.4. Minimal data is available on the risk of lung cancer in individuals with MBL, particularly LC-MBL, a condition impacting an estimated 15 million individuals over 40 years of age in the United States. Here, we evaluated the risk of incident lung cancer in the largest cohort of individuals systematically screened for MBL to date.
Methods: Participants from the Mayo Clinic MBL Biobank, which includes ~10,500 individuals aged ≥40 years with no prior history of hematologic malignancy, were screened for MBL using eight-color flow cytometry. This analysis included 7,996 individuals with no prior history of lung cancer who resided within the 27-county region surrounding Mayo Clinic in Rochester, Minnesota, and had comprehensive medical records available for ascertainment of incident lung cancer. Incident lung cancer cases were identified by ≥2 International Classification of Diseases codes in the electronic medical record. All diagnoses were confirmed by manual review, with the reviewer blinded to MBL status. Cigarette smoking history (ever/never) was obtained from self-reported questionnaires. Time to incident lung cancer was calculated from MBL screening to the earliest date of incident lung cancer diagnosis, withdrawal, death, last medical visit, or study end. Cox regression was used to estimate hazard ratios (HR) and 95% confidence intervals (CIs) for the association between MBL status and incident lung cancer, adjusting for age, sex, and smoking status. Cumulative incidence was computed using the Aalen-Johansen method, with death as a competing event. Inverse probability weighting was applied to balance age and sex distributions across groups.
Results: Among 7,996 participants screened for MBL, 1,196 (15%) had CLL-type MBL (96% LC-MBL) and 195 (2%) had non-CLL type MBL. The median ages by MBL status were: 71 (LC-MBL), 74 (HC-MBL), 78 (non-CLL type MBL) and 65 (no MBL).
Median follow-up was 6.3 years (range 0-16.7); 76 individuals developed incident lung cancer (19 with LC-MBL, 1 with HC-MBL, 2 with non-CLL-type MBL, and 54 with no MBL). Among individuals who developed lung cancer, 62 (82%) had a history of smoking. The median age at lung cancer diagnosis was 76 years (range 46-95). The lung cancer stage distribution was as follows: 31 (45%) stage 0-1, 12 (17%) stage II-III, and 26 (38%) stage IV. Non-small cell lung cancer (NSCLC) was the most common histologic subtype (n=54, 71%), including 41 (76%) adenocarcinoma, 12 (22%) squamous cell carcinoma, and 1 (2%) mixed adenosquamous carcinoma.
Compared to individuals without MBL, those with CLL-type MBL had a 1.8-fold risk (95%CI: 1.1-3.1, P=0.023) of incident lung cancer, after adjusting for age, sex and smoking status. These findings remained consistent when the analysis was restricted to individuals with LC-MBL (HR=1.8, 95%CI: 1.1-3.1, P=0.027). The estimated 5-year cumulative incidence of lung cancer was 0.9% (95%CI: 0.5-1.7%) among individuals with LC-MBL and 0.5% (95%CI: 0.4-0.8%) in those without MBL. The 10-year cumulative incidence was 2.5% (95%CI: 1.2-5.1%) in those with LC-MBL and 1.0% (95%CI: 0.7-1.4%) in those without MBL. We did not observe a significant association between LC-MBL status and the development of NSCLC histology subtype (HR=1.2, 95%CI: 0.6-2.5).
Conclusions: LC-MBL is associated with a 1.8-fold increased risk of incident lung cancer, after adjusting for age, sex and smoking status. These findings suggest that the increased risk of lung cancer among individuals with CLL may be present as early as the LC-MBL phase. Given the high prevalence of LC-MBL, even a modest increase in lung cancer risk could have important population-level implications. Future studies are needed to investigate its underlying biological mechanisms.
DISCLOSURES
Yuan Yao, MD, MS: No relevant conflicts of interest to declare.